Barrington Upgrades LeMaitre Vascular(LMAT.US) to Buy Rating, Maintains Target Price $95
Barrington has upgraded LeMaitre Vascular (LMAT.US) from an "Outperform" to a "Buy" rating. The firm has also decided to maintain its target price for the stock at $95. This upgrade reflects Barrington's increased confidence in the company's future performance.
Avoiding Lag: Real-Time Signals in (LMAT) Movement
The article provides a real-time analysis of Lemaitre Vascular Inc. (NASDAQ: LMAT) stock movement, highlighting strong near-term sentiment but a neutral mid- and long-term outlook. It includes AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis with support and resistance levels. The report also notes an ongoing breakdown and elevated downside risk for LMAT.
LeMaitre Vascular stock hits 52-week low as analysts hold
LeMaitre Vascular (LMAT) reached a new 52-week low of USD 78.22, despite analysts holding an average price target of USD 110.60. The company's second-quarter revenue of USD 70.38 million missed consensus estimates, as did diluted earnings per share, leading to a focus on execution against expectations. Despite the miss, revenue grew by 9.60% year-over-year, and the company provided positive 2026 full-year sales and earnings per share guidance.
LeMaitre Vascular, Inc. (LMAT) Stock Forecasts
Argus has raised its target price for LeMaitre Vascular, Inc. (LMAT) to $89.00. The current price for LMAT is $80.19. LeMaitre Vascular Inc. specializes in manufacturing and distributing medical devices for peripheral vascular disease.
140,936 Shares of LeMaitre Vascular, Inc. $LMAT Purchased by Bank of America Corp DE
Bank of America Corp DE recently acquired 140,936 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, valued at approximately $13.5 million. This purchase makes Bank of America a 0.62% owner of the medical instruments supplier, whose stock is largely held by institutional investors at 84.64%. Despite missing recent earnings estimates, LeMaitre Vascular announced a quarterly dividend of $0.25 per share, and analysts currently hold a "Hold" consensus rating on the stock with an average price target of $110.60.
LMAT6268257 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the LMAT6268257 bond issued by LeMaitre Vascular, Inc., highlighting its key features, coupon and redemption information. It details the issuer's profile, bond classification, credit risk assessment, and upcoming coupon payout schedule. The bond has a 2.5% fixed rate, semi-annual coupon payments, and matures on February 1, 2030.
LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed
Edelson Lechtzin LLP is investigating potential class-action claims against LeMaitre Vascular following a reported data breach that exposed customer data. The law firm is offering free case evaluations to individuals who may have been affected, as personal information such as Social Security numbers, government IDs, and health records could be at risk. The investigation aims to recover compensation for affected individuals and encourage LeMaitre Vascular to enhance its data protection measures.
LeMaitre Vascular faces data breach exposing personal info; free legal help offered to affected individuals.
LeMaitre Vascular, a medical technology company, has experienced a data breach that may have exposed sensitive personal information, including Social Security numbers and health records. The breach, disclosed around September 18, 2026, has prompted law firm Edelson Lechtzin LLP to offer free legal evaluations and investigate a class-action lawsuit for affected individuals. The article also provides context with recent health-sector market data, showing a general decline in US health-sector stocks.
LeMaitre Vascular stock holds at USD 79.13 as valuation draws scrutiny
LeMaitre Vascular stock traded at USD 79.13 on September 22, 2026, with a market capitalization of USD 1.81 billion. The company, which specializes in medical devices for vascular surgeons, has a forward price-to-earnings ratio of 25.8. This valuation indicates that the company is valued for continuing earnings, highlighting the importance of operating growth.
Understanding the Setup: (LMAT) and Scalable Risk
This article provides an AI-driven analysis of Lemaitre Vascular Inc. (LMAT), highlighting weak near-term sentiment and elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal data for near-term, mid-term, and long-term perspectives.
LeMaitre Vascular stock hits 52-week low at 78.22 USD By Investing.com
LeMaitre Vascular Inc. (LMAT) stock has dropped to a 52-week low of $78.22, marking a 14.55% decrease over the past year and trading 33% below its 52-week high. Despite the decline, InvestingPro data indicates strong financial health and the company has consistently raised its dividend for 15 years. The recent fall follows second-quarter earnings that missed analyst expectations and a revised downward full-year growth outlook.
LeMaitre Vascular Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach at LeMaitre Vascular, Inc. that may have compromised the personal information of customers and patients. The breach, which exposed Social Security numbers, medical records, and driver's licenses, affects at least 955 people in Massachusetts. Individuals whose information was compromised may be entitled to compensation and are encouraged to contact the law firm.
LeMaitre Vascular Data Breach Exposes Social Security Numbers
LeMaitre Vascular Inc., a medical device company, has disclosed a data breach affecting 955 Massachusetts residents, exposing sensitive personal and medical information including Social Security numbers, medical records, and driver's licenses. The company is offering 24 months of complimentary identity protection services through TransUnion to affected individuals. Notification letters were sent on September 18, 2026, though details about the incident's timeline were not provided.
LeMaitre Vascular stock hits 52-week low at 78.22 USD
LeMaitre Vascular Inc. (LMAT) stock has dropped to a 52-week low of $78.22, marking a 14.55% decrease over the past year and trading 33% below its 52-week high. Despite this, InvestingPro data indicates "GREAT" financial health and a low PEG ratio, with the company consistently raising dividends for 15 years and holding more cash than debt. The recent decline follows second-quarter earnings that missed Wall Street expectations and a revised downward full-year growth outlook.
LeMaitre Vascular stock hits 52-week low at 78.22 USD
LeMaitre Vascular Inc. (LMAT) stock recently hit a 52-week low of $78.22, reflecting a 14.55% decrease over the past year and trading 33% below its 52-week high. Despite the market downturn, InvestingPro data indicates the company has "GREAT" financial health, a PEG ratio of 0.7, and has consistently raised its dividend for 15 consecutive years while maintaining more cash than debt. This decline follows the company missing Wall Street's second-quarter earnings and revenue expectations and a downward revision of its full-year growth outlook.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of "Hold" from Brokerages
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average "Hold" rating from nine brokerages, with an average 12-month price target of $110.60. The company's shares opened at $78.87, near its 52-week low, and its recent quarterly earnings of $0.74 EPS on $70.38 million in revenue missed analyst expectations, despite a 9.6% year-over-year revenue growth. Several analysts have recently downgraded their ratings or cut price targets for LMAT.
LeMaitre Vascular (LMAT) CFO adds dividend-linked share rights
LeMaitre Vascular's CFO, Dorian Paul LeBlanc, was granted additional Dividend Equivalent Rights (DERs) on September 3, 2026. These rights are tied to previous restricted stock unit (RSU) awards from March and December 2025 and are the economic equivalent of 6.5593 shares of common stock. The transaction is considered a neutral impact on equity-based compensation as it reflects accrued dividends on existing RSU grants.
Legal & General Group Plc Invests $4.84 Million in LeMaitre Vascular, Inc. $LMAT
Legal & General Group Plc has acquired a new stake in LeMaitre Vascular, Inc. worth approximately $4.84 million, purchasing 50,434 shares. This investment gives Legal & General Group Plc a 0.22% ownership in the medical instruments supplier, while institutional investors collectively hold 84.64% of the company's stock. LeMaitre Vascular recently reported Q2 EPS of $0.74, missing consensus estimates, but analysts anticipate full-year EPS of $2.89, with the stock currently trading near its 12-month low.
Corient Private Wealth LP Purchases New Position in LeMaitre Vascular, Inc. $LMAT
Corient Private Wealth LP has acquired a new stake of 25,619 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $2.46 million during the second quarter. This purchase contributes to the 84.64% institutional ownership of the company. Despite LeMaitre Vascular missing its Q2 earnings and revenue estimates, the company's revenue increased by 9.6% year-over-year, and it declared a quarterly dividend of $0.25 per share.
Man Group plc Buys Shares of 29,417 LeMaitre Vascular, Inc. $LMAT
Man Group plc recently acquired 29,417 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) for approximately $2.82 million, establishing a 0.13% stake in the medical instruments supplier. The stock currently has a "Hold" consensus rating from analysts with an average target price of $110.60, despite the company missing its latest quarterly earnings and revenue expectations. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.
Speculative Rally Weighed on LeMaitre Vascular (LMAT)
Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 in Q2 2026 due to a speculative rally favoring high-beta stocks, which negatively impacted their quality-focused approach and healthcare holdings like LeMaitre Vascular (LMAT). Despite LMAT's 12% decline in the quarter, Riverwater Partners maintains that the company's fundamental strengths, including niche leadership and consistent execution, remain intact, viewing the weakness as sentiment-driven. While acknowledging LMAT's potential, the firm is also exploring AI stocks with greater upside and less downside risk.
Bank of New York Mellon Corp Invests $16.55 Million in LeMaitre Vascular, Inc. $LMAT
Bank of New York Mellon Corp has acquired a new stake of $16.55 million in LeMaitre Vascular, Inc., purchasing 172,458 shares. This investment means institutional investors now collectively own 84.64% of LMAT, despite the company recently missing quarterly earnings estimates and receiving a mixed "Hold" consensus rating from analysts. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.
LeMaitre Vascular, Inc. $LMAT Stock Position Raised by Grandeur Peak Global Advisors LLC
Grandeur Peak Global Advisors LLC significantly increased its stake in LeMaitre Vascular, Inc. (LMAT) by 63.1% in the second quarter, making it their 7th largest position. Despite this increased institutional interest, LeMaitre Vascular's recent quarterly results missed analyst expectations, and the company currently holds a consensus "Hold" rating with an average price target of $110.60. The medical instruments supplier also declared a quarterly dividend of $0.25 per share.
Deutsche Bank AG Purchases Shares of 24,080 LeMaitre Vascular, Inc. $LMAT
Deutsche Bank AG has acquired 24,080 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $2.31 million. Despite this investment and significant institutional ownership, several analysts have recently downgraded the stock to "Hold" due to missed earnings and revenue expectations. The company also declared a quarterly dividend of $0.25 per share.
Grandeur Peak Global Advisors LLC Invests $15.45 Million in LeMaitre Vascular, Inc. $LMAT
Grandeur Peak Global Advisors LLC has acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT), purchasing 161,010 shares valued at approximately $15.45 million, making it their ninth-largest holding. This investment comes as LeMaitre Vascular reported quarterly earnings that missed analyst expectations, with an EPS of $0.74 against an anticipated $0.81 and revenue of $70.38 million compared to $71.47 million expected. Despite the earnings miss, the company announced a quarterly dividend of $0.25, contributing to a 1.3% annualized yield, while analysts maintain a consensus "Hold" rating with an average price target of $110.60.
LeMaitre to Participate at Upcoming Investor Conferences in September
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its CFO, Dorian LeBlanc, will participate in three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the 19th Annual Barrington Research Virtual Fall Investment Conference. LeMaitre is a medical device company focused on treating peripheral vascular disease.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre Vascular (LMAT) has experienced a significant 17.2% decline in its stock price over the past four weeks, making it technically oversold. This, combined with a strong consensus among Wall Street analysts for better-than-expected earnings and a Zacks Rank #2 (Buy), suggests the stock is poised for a potential rebound. The Relative Strength Index (RSI) reading of 28.47 indicates that selling pressure may be exhausting, further supporting a turnaround.
Lemaitre Vascular stock hits 52-week low at 78.64 USD
Lemaitre Vascular (LMAT) stock has fallen to a 52-week low of $78.64, trading just 1% above its lowest point. This decline reflects a challenging period for the medical device manufacturer, despite its strong fundamentals and "GREAT" financial health score, with an InvestingPro analysis suggesting it is undervalued. The recent drop follows second-quarter earnings that missed Wall Street's expectations, leading the company to revise its full-year growth outlook downward.
Lemaitre Vascular stock hits 52-week low at 78.64 USD
Lemaitre Vascular (LMAT) stock recently hit a 52-week low of $78.64, trading just 1% above this mark. Despite a 16.96% decline over the past year, the company maintains strong fundamentals, including a "GREAT" financial health score and an attractive PEG ratio of 0.71. This valuation comes after Q2 earnings missed Wall Street expectations, leading to a revised full-year growth outlook.
LeMaitre Vascular (LMAT) Could Be 26% Undervalued On Mixed Valuation Views
LeMaitre Vascular (LMAT) has seen its share price drop by about 17% in the last month, prompting questions about its valuation. While one narrative suggests the stock is 25.6% undervalued with a fair value of $110, driven by an expanding patient population and revenue growth assumptions, another view using a Discounted Cash Flow (DCF) model indicates it is overvalued at its current price of $81.86, suggesting a fair value of $69.97. Investors are encouraged to review the mixed data and consider various risk factors.
Ranger Investment Management L.P. Purchases New Shares in LeMaitre Vascular, Inc. $LMAT
Ranger Investment Management L.P. acquired 219,307 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $21.0 million during the second quarter, representing 0.96% of the company's stock. LeMaitre Vascular reported quarterly earnings of $0.74 per share, missing the consensus estimate, with revenue increasing 9.6% year over year. The company also declared a quarterly dividend of $0.25 per share, and analysts currently hold a "Hold" rating for the stock with an average price target of $110.60.
Emerald Investment Advisers LLC Takes $3.49 Million Position in LeMaitre Vascular, Inc. $LMAT
Emerald Investment Advisers LLC has acquired a new position of 36,366 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $3.49 million during the second quarter. Other institutional investors like Illinois Municipal Retirement Fund and Federated Hermes Inc. have also adjusted their stakes in the medical instruments supplier. LeMaitre Vascular's stock opened at $81.86, with a market cap of $1.87 billion, and recently announced a quarterly dividend of $0.25 per share.
ETFs Investing in LeMaitre Vascular, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of LeMaitre Vascular, Inc. It provides detailed information for each ETF, including market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs cover a range of investment strategies, primarily focusing on small-cap and extended market segments, with some specializing in health care and dividend achievers.
Summit Creek Advisors LLC Buys New Stake in LeMaitre Vascular, Inc. $LMAT
Summit Creek Advisors LLC acquired a new stake of 49,174 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the second quarter, valued at approximately $4.72 million. Other hedge funds also adjusted their positions in the medical instruments supplier. The company recently reported its quarterly earnings, missing analyst estimates, and announced a quarterly dividend of $0.25 per share.
Bank of America Corp DE Increases Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Bank of America Corp DE increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 39.0% in the first quarter, now owning 180,095 shares worth $19.66 million. Several other institutional investors also adjusted their positions in the medical instruments supplier. LeMaitre Vascular recently reported Q1 earnings that missed analyst estimates and declared a quarterly dividend of $0.25 per share.
Rice Hall James & Associates LLC Purchases Shares of 189,907 LeMaitre Vascular, Inc. $LMAT
Rice Hall James & Associates LLC recently acquired 189,907 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, totaling approximately $18.2 million and representing 0.83% of the company. Despite institutional ownership reaching 84.64%, LeMaitre Vascular missed quarterly earnings and revenue estimates, though revenue still grew by 9.6% year-over-year. The company declared a $0.25 quarterly dividend, and analysts currently hold an average "Hold" rating with a target price of $110.60.
Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
This article analyzes the Q2 earnings of LeMaitre (NASDAQ:LMAT) and compares its performance with other companies in the surgical equipment & consumables - specialty sector. While the overall sector reported satisfactory Q2 results with revenues beating estimates, LeMaitre delivered the weakest performance against analyst estimates and saw its stock drop significantly. In contrast, Teleflex (NYSE:TFX) had the fastest revenue growth, and Intuitive Surgical (NASDAQ:ISRG) achieved the biggest analyst estimate beat.
LeMaitre Vascular (NasdaqGM:LMAT) Stock Forecast & Analyst Predictions
LeMaitre Vascular (LMAT) is forecast to grow earnings by 8.5% and revenue by 8.7% annually. Analysts have a price target of US$110, 35% above the current price, despite the stock being down 12% over the past year and recent earnings missing estimates. The company recently announced a quarterly dividend of US$0.25 and provided earnings guidance for upcoming quarters and full year 2026.
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 revenue outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. This guidance reduction, despite growth, highlights operational risks and may lead some investors to adopt a more cautious view, though the company's long-term narrative projects significant revenue and earnings growth. The article advises investors to form their own verdict by exploring the company's financial health and other fair value estimates.
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Despite these challenges, the company reinforced its growth narrative, though the revised guidance highlights operational risks. Investors should consider the updated forecast of $274.3-$278.3 million in sales and $2.84-$2.94 EPS for 2026, which represents a modest trim from prior targets.
LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.
LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the valuation reset, its 11% organic growth guidance, solid balance sheet, and expanding biologics portfolio make it a compelling buy, with a price target adjusted to $95-$100 for year-end 2027.
LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 39% Potential Upside in the Healthcare Sector
LeMaitre Vascular, Inc. (LMAT), a healthcare sector player specializing in vascular surgery medical devices, shows a potential upside of 39.33% with an average target price of $113.13. Despite trading below its 50-day and 200-day moving averages, the company exhibits strong operational efficiency, a healthy free cash flow, and a positive outlook from analysts. Its diverse product portfolio and strategic market positioning make it an attractive investment for growth-seeking investors.
LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?
LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% below an estimated fair value of $118.75, primarily due to expectations of strong revenue growth and improved margins from its product pipeline.
Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT
Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing Q2 revenue and earnings estimates, although it did report a 9.6% year-over-year revenue growth.
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
LeMaitre Vascular, Inc. recently missed its statutory earnings estimates, causing its shares to drop by 21%. Despite the earnings miss, revenue remained in line with predictions, and analysts have largely maintained their price targets, though they slightly downgraded next year's EPS forecasts. The company is still expected to grow faster than the overall industry, with long-term prospects remaining positive according to analysts.
31% Undervalued? LeMaitre Vascular (LMAT) After Earnings Guidance And Dividend Update
LeMaitre Vascular (LMAT) reported strong Q2 2026 results with increased sales and net income, affirming its quarterly dividend. While analysts view the stock as 31.4% undervalued with a fair value of $118.75 due to a strong product pipeline and pricing power, Simply Wall St's DCF model suggests it is overvalued at $81.45 compared to an estimated future cash flow value of $69.27. Investors are encouraged to review these differing valuations and consider the company's risks and opportunities.
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
LeMaitre Vascular (NASDAQ: LMAT) shares fell 21% after missing statutory earnings estimates, though revenues were in line with predictions. Analysts have since slightly downgraded their earnings per share forecasts for 2026, yet the consensus price target remained unchanged at US$114, implying that the valuation is not expected to be significantly impacted. The company is still projected to grow revenues faster than the broader industry.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, where management will hold investor meetings on August 11, 2026. The company specializes in providing devices, implants, and services for treating peripheral vascular disease, catering to vascular surgeons. Additional information about LeMaitre, including its contact details, is available on its website.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, scheduled for Tuesday, August 11, 2026. Management will hold investor meetings at this event. LeMaitre is a medical device company specializing in products for peripheral vascular disease.
LeMaitre management to meet investors at virtual Aug. 11 event
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices and services for peripheral vascular disease.
